S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer

Molecular Cancer Research

Volumn 10, Issue 9, 2012, Pages 1203-1215

  Switzer, Christopher H ^a   Glynn, Sharon A ^a   Cheng, Robert Y S ^a   Ridnour, Lisa A ^a   Green, Jeffrey E ^a   Ambs, Stefan ^a   Wink, David A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; HERMES ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; MYC PROTEIN; NITRIC OXIDE; PACLITAXEL; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STAT3 PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RESISTANCE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUSE; NITROSYLATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; BETA CATENIN; BREAST NEOPLASMS; CARCINOMA, BASAL CELL; CELL LINE, TUMOR; COCULTURE TECHNIQUES; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MACROPHAGES; MICE; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; NITROSATION; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 84866497973     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-12-0124     Document Type: Article

References (47)

1. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
2. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568-81.
3. Sarrio D, Rodriguez-Pinilla SMA, Hardisson D, Cano A, Moreno-Bueno G, Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008;68:989-97.
4. Marchini C, Montani M, Konstantinidou G, Orrù R, Mannucci S, Ramadori G, et al. Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies. PLoS One 2010;5:e14131.
5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 2006;295:2492-502.
6. Reis-Filho JS, Tutt ANJ. Triple negative tumours: a critical review. Histopathology 2008;52:108-18.
7. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008;14:1368-76.
8. Hoadley KA, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, et al. EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 2007;8:258.
9. Khramtsov AI, Khramtsova GF, Tretiakova M, Huo D, Olopade OI, Goss KH. Wnt/{beta}-catenin pathway activation is enriched in basallike breast cancers and predicts poor outcome. Am J Pathol 2010;176:2911-20.
10. Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, et al. [beta]-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation. Mod Pathol 2011;24:209-31.
11. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, b-catenin, and ZEB1 in malignant progression of cancer. Cancer Met Rev 2009;28:151-66.
12. Polette M, Mestdagt M, Bindels S, Nawrocki-Raby B, Hunziker W, Foidart JM, et al. Beta-catenin and ZO-1: shuttle molecules involved in tumor invasion-associated epithelial-mesenchymal transition processes. Cells Tissues Organs 2007;185:61-5.
13. Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, et al. The CD44+/CD24- phenotype is enriched in basallike breast tumors. Breast Cancer Res 2008;10:R53.
14. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011;146:53-66.
15. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000;6:4768-75.
16. Wink DA, Ridnour LA, Hussain SP, Harris CC. The reemergence of nitric oxide and cancer. Nitric Oxide 2008;19:65-7.
17. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 2010;120:3843-54.
18. Thomas DD, Ridnour LA, Espey MG, Donzelli S, Ambs S, Hussain SP, et al. Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem 2006;281:25984-93.
19. Espey MG, Miranda KM, Pluta RM, Wink DA. Nitrosative capacity of macrophages is dependent on nitric-oxide synthase induction signals. J Biol Chem 2000;275:11341-7.
20. Ridnour LA, Thomas DD, Switzer C, Flores-Santana W, Isenberg JS, Ambs S, et al. Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide 2008;19:73-6.
21. Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006;8:1329-37.
22. Jaffrey SR, Snyder SH. The biotin switch method for the detection of S-nitrosylated proteins. Sci. STKE 2001, pl1 (2001).
23. Rahman MA, Senga T, Ito S, Hyodo T, Hasegawa H, Hamaguchi M. S-nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric oxide-mediated cell invasion. J Biol Chem 2010;285:3806-14.
24. Ingthorsson S, Halldorsson T, Sigurdsson V, Frioriksdottir AJ, Bodvarsdottir SK, Steinarsdottir M, et al. Selection for EGFR gene amplification in a breast epithelial cell line with basal-like phenotype and hereditary background. In Vitro Cell Dev Biol Anim 2011;47:139-48.
25. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8.
26. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44CD24 stem cell-like breast cancer cells in human tumors. J Clin Invest 2011;121:2723-35.
27. Switzer CH, Glynn SA, Ridnour LA, Cheng RY, Vitek MP, Ambs S, et al. Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci 2011;32:644-51.
28. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14:152-60.
29. Eichhorn PJA, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (BBA)-Rev Cancer 2009;1795:1-15.
30. Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 1992;257:1261-4.
31. DiMeo TA, Anderson K, Phadke P, Fan C, Feng C, Perou CM, et al. A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 2009;69:5364-73.
32. Foroni C, Broggini M, Generali D, Damia G. Epithelial-mesenchymal transition and breast cancer: Role, molecular mechanisms, and clinical impact. Cancer Treat Rev 2012;38:689-97.
33. Ogunwobi OO, Liu C. Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin Exp Metastasis 2011;28:721-31.
34. St John MA, Dohadwala M, Luo J, Wang G, Lee G, Shih H, et al. Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma. Clin Cancer Res 2009;15:6018-27.
35. Neil JR, Johnson KM, Nemenoff RA, Schiemann WP.Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis 2008;29:2227-35.
36. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85.
37. Kuroda H, Ishida F, Nakai M, Ohnisi K, Itoyama S. Basal cytokeratin expression in relation to biological factors in breast cancer.HumPathol 2008;39:1744-50.
38. Cheng R, Ridnour LA, Glynn SA, et al. Nitric oxide and cancer: An overview. In:Bonavida B, editor. Nitric oxide (NO) and cancer. New York: Springer; 2010. p. 3-20.
39. 2 reaction. Chem Res Toxicol 2007;20:709-14.
40. 2 within the hydrophobic interior of biological membranes. Proc Natl Acad Sci U S A 1998;95:2175-9.
41. Foster MW, Hess DT, Stamler JS. Protein S-nitrosylation in health and disease: a current perspective. Trends Mol Med 2009;15:391-404.
42. Marozkina NV, Gaston B. S-Nitrosylation signaling regulates cellular protein interactions. Biochim Biophys Acta 2011;1820:722-29.
43. Lam YW, Yuan Y, Isaac J, Babu CVS, Meller J, Ho S-M. Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells. PLoS One 2010;5:e9075.
44. Lee TY, Chen YJ, Lu TC, Huang HD. SNOSite: exploiting maximal dependence decomposition to identify cysteine S-nitrosylation with substrate site specificity. PLoS One 2011;6:e21849.
45. Estrada C, Gomez C, Martin-Nieto J, De Frutos T, Jimenez A, Villalobo A. Nitric oxide reversibly inhibits the epidermal growth factor receptor tyrosine kinase. Biochem J 1997;326:369-76.
46. Maegawa RO, Tang SC. Triple-negative breast cancer: unique biology and its management. Cancer Invest 2010;28:878-83.
47. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001;5:62-71.